CA2674382C - High affinity antibodies that neutralize staphylococcus enterotoxin b - Google Patents

High affinity antibodies that neutralize staphylococcus enterotoxin b Download PDF

Info

Publication number
CA2674382C
CA2674382C CA2674382A CA2674382A CA2674382C CA 2674382 C CA2674382 C CA 2674382C CA 2674382 A CA2674382 A CA 2674382A CA 2674382 A CA2674382 A CA 2674382A CA 2674382 C CA2674382 C CA 2674382C
Authority
CA
Canada
Prior art keywords
seq
antibody
antigen
amino acid
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2674382A
Other languages
English (en)
French (fr)
Other versions
CA2674382A1 (en
Inventor
Philip M. Sass
Nicholas C. Nicolaides
Luigi Grasso
Marc Berger
Tao Sai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Priority to CA2924155A priority Critical patent/CA2924155C/en
Publication of CA2674382A1 publication Critical patent/CA2674382A1/en
Application granted granted Critical
Publication of CA2674382C publication Critical patent/CA2674382C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2674382A 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylococcus enterotoxin b Active CA2674382C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2924155A CA2924155C (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylococcus enterotoxin b

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88327107P 2007-01-03 2007-01-03
US60/883,271 2007-01-03
US88840507P 2007-02-06 2007-02-06
US60/888,405 2007-02-06
PCT/US2008/000104 WO2008085878A2 (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylcoccus enterotoxin b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2924155A Division CA2924155C (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylococcus enterotoxin b

Publications (2)

Publication Number Publication Date
CA2674382A1 CA2674382A1 (en) 2008-07-17
CA2674382C true CA2674382C (en) 2016-05-31

Family

ID=39529113

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2674382A Active CA2674382C (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylococcus enterotoxin b
CA2924155A Active CA2924155C (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylococcus enterotoxin b

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2924155A Active CA2924155C (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylococcus enterotoxin b

Country Status (9)

Country Link
US (6) US8236932B2 (enExample)
EP (2) EP3138852A1 (enExample)
JP (3) JP5412293B2 (enExample)
AU (1) AU2008205376B2 (enExample)
CA (2) CA2674382C (enExample)
DK (1) DK2109622T3 (enExample)
ES (1) ES2619943T3 (enExample)
PL (1) PL2109622T3 (enExample)
WO (1) WO2008085878A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674382C (en) 2007-01-03 2016-05-31 Morphotek, Inc. High affinity antibodies that neutralize staphylococcus enterotoxin b
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2013089877A2 (en) * 2011-09-27 2013-06-20 Albert Einstein College Of Medicine Of Yeshiva University Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
WO2013076139A1 (en) * 2011-11-23 2013-05-30 F. Hoffmann-La Roche Ag Cd40l expressing mammalian cells and their use
US20160039914A1 (en) * 2013-03-14 2016-02-11 Albert Einstein College Of Medicine Of Yeshiva University Humanized antibodies specific for staphylococcal enterotoxin b
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
AU2017363309A1 (en) * 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
KR102124258B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 황색 포도알균 장독소 b 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
AU2020376934A1 (en) 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof
KR102274759B1 (ko) * 2020-01-16 2021-07-09 대한민국(질병관리청장) 황색포도알균 장독소 b에 특이적인 항체 및 이의 용도
CN119101153B (zh) * 2024-04-30 2025-07-08 中国人民解放军军事科学院军事医学研究院 一种葡萄球菌肠毒素b纳米抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574089A (en) 1948-06-08 1951-11-06 Cochran Jacqueline Luggage case having a removable lining
US4854432A (en) 1988-07-06 1989-08-08 American Tourister, Inc. Suitcase having removable divider with clothing pockets
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
AU3093395A (en) 1994-07-06 1996-01-25 Truckin' Movers Corporation Convertible carrying case and work platform
US6036697A (en) 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
EP1127132A1 (en) * 1998-10-07 2001-08-29 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20050240009A1 (en) * 2002-08-21 2005-10-27 Carr Francis J T-cell epitopes in staphylococcal enterotoxin b
JP4571586B2 (ja) * 2003-09-05 2010-10-27 一般財団法人化学及血清療法研究所 プロテアーゼ耐性ｓｅｂ改変体およびそれを含むワクチン
EP1860120B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
CA2674382C (en) * 2007-01-03 2016-05-31 Morphotek, Inc. High affinity antibodies that neutralize staphylococcus enterotoxin b

Also Published As

Publication number Publication date
US20180094048A1 (en) 2018-04-05
US20140072553A1 (en) 2014-03-13
AU2008205376B2 (en) 2012-07-12
US9868780B2 (en) 2018-01-16
EP2109622B1 (en) 2016-11-09
JP2016146824A (ja) 2016-08-18
CA2924155A1 (en) 2008-07-17
US20120171223A1 (en) 2012-07-05
JP5412293B2 (ja) 2014-02-12
WO2008085878A3 (en) 2009-02-26
CA2674382A1 (en) 2008-07-17
US10364284B2 (en) 2019-07-30
WO2008085878A2 (en) 2008-07-17
ES2619943T3 (es) 2017-06-27
US20150050276A1 (en) 2015-02-19
US20130183314A1 (en) 2013-07-18
CA2924155C (en) 2020-02-11
US8236932B2 (en) 2012-08-07
JP5881646B2 (ja) 2016-03-09
US8895704B2 (en) 2014-11-25
JP2013216673A (ja) 2013-10-24
DK2109622T3 (en) 2017-02-13
EP2109622A2 (en) 2009-10-21
US20170121396A1 (en) 2017-05-04
PL2109622T3 (pl) 2017-06-30
EP3138852A1 (en) 2017-03-08
AU2008205376A1 (en) 2008-07-17
JP6195946B2 (ja) 2017-09-13
JP2010514459A (ja) 2010-05-06
US9359428B2 (en) 2016-06-07
US8889846B2 (en) 2014-11-18

Similar Documents

Publication Publication Date Title
US10364284B2 (en) High affinity antibodies that neutralize Staphylococcus enterotoxin B
US20240182548A1 (en) Sars-cov-2 antibodies and methods of selecting and using the same
US20230331824A1 (en) Single-domain antibodies that bind sars-cov-2
US20200164069A1 (en) Binding molecules specific for il-21 and uses thereof
KR20110025859A (ko) 항-ｇｄ２ 항체 및 이와 관련된 방법 및 용도
TR201808486T4 (tr) Bradikinin B1 reseptör ligandlarına karşı antikorlar.
WO2022150740A1 (en) Cross-reactive antibodies recognizing the coronavirus spike s2 domain
CN114430746B (zh) 新型抗pd-l1抗体
AU2012241059B2 (en) High affinity antibodies that neutralize Staphylococcus enterotoxin B
WO2021194965A1 (en) Superhuman anti-sars-cov-2 antibodies and uses thereof
US20240294611A1 (en) Cross-reactive antibodies recognizing the coronavirus spike s2 domain
WO2024211789A1 (en) Cross-flavivirus binding domains and uses thereof
CN120225558A (zh) 针对人程序性细胞死亡蛋白1(pd-1)的单克隆抗体
NZ725735B2 (en) Binding molecules specific for il-21 and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121210

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260216